Background: Treatment for recurrent or advanced/metastatic non-small cell lung cancer (aNSCLC) has advanced in the past 5 years with immunotherapy (IO). This study sought to describe first-line (1L) aNSCLC treatment patterns and clinical outcomes. Methods: In this retrospective. multisite cohort study. https://www.roneverhart.com/Cyspera-Pigment-Corrector-1-75oz-52ml/